Introduction: Different sexual function-preserving surgical techniques aimed at improving voiding and sexual function in patients undergoing radical cystectomy for bladder cancer have been described. The objective of this systematic review is to determine the effect of sexual function-preserving cystectomy (SPC) on functional and oncological outcomes.
Introduction
Radical cystectomy remains the standard procedure for patients with muscle-invasive bladder cancer (MIBC) or http://dx.doi.org/10.1016/j.urolonc.2017.04.013 1078-1439/r 2017 Elsevier Inc. All rights reserved.
non-muscle-invasive bladder cancer with either high risk of progression or following failure of intravesical therapy [1, 2] . This technique is associated with significant morbidity and a high prevalence of postoperative erectile dysfunction, which may have a major effect on quality of life, especially in younger patients [3, 4] . Several attempts at sexual-preserving surgery have been reported to minimize effect on quality of life. A neuroanatomical approach to radical cystoprostatectomy with preservation of sexual function was first described by Shlegel and Walsh in 1987 [5] . They suggested that the main reason for postoperative erectile dysfunction was the injury to the pelvic nerve plexus, and proposed a modification over the standard procedure that consisted of the preservation of the cavernous nerves. Several modifications to this technique have been described to date, aiming at improving voiding and sexual function in patients undergoing radical cystectomy for bladder cancer (BC) [6, 7] .
Technical variations range from complete prostate preservation to other procedures where the prostate is partly or completely removed, preserving the vasa deferentia, seminal vesicles and ejaculatory ducts [8] . There is a lack of consensus regarding the best approach from a functional perspective and different expectations regarding the results. Furthermore, it is not known if such techniques have a detrimental effect on oncological control.
The objective of this systematic review is to determine the effect of prostate, capsule or nerve-sparing cystectomy on sexual function, oncological outcomes and urinary continence compared with standard radical cystectomy in men with BC.
Materials and methods

Evidence acquisition
Search strategy
The study protocol was published in the PROSPERO database [9] . The review was performed in line with the preferred reporting items for systematic reviews and metaanalysis statement [10] using the methods outlined in the Cochrane handbook for systematic reviews [11] . The databases searched were MEDLINE, Embase, and Cochrane central register of controlled trials, Cochrane database of systematic reviews and Cochrane health technology assessment databases and clinicaltrial.gov. The search strategy is available in Appendix 1. Only studies published from the year 2000 onward were included to reflect current clinical practice. The search was supplemented by hand searching the reference list of European Association of Urology (EAU) guidelines on BC. The study steering group (EAU muscle-invasive and metastatic BC guideline panel) provided clinical expertise and advice. Relevant trialists and organizations were contacted to identify any additional relevant articles. No language restrictions were applied. The review was commissioned by the EAU muscle-invasive and metastatic BC guideline panel as part of its guideline update for 2016.
Following deduplication, all abstracts and eligible full text articles were independently screened by different reviewers (V.H., E.L.E., and J.D.). Any disagreements were resolved by discussion or by consulting a third independent party (S.M. or T.L.) who acted as an arbiter.
Types of study design included
All study designs incorporating the relevant interventions were eligible, including randomised controlled trials (RCTs), quasi-randomised controlled trials, prospective and retrospective nonrandomised comparative studies (NRCSs), including studies with historical controls as control group and observational studies, and single-arm case series. Conference meeting abstracts with no subsequent full text report were excluded. For inclusion, studies needed to have a minimum follow-up of 1 year, comparative studies needed to have recruited at least 30 participants, and case series needed at least 50 participants.
Types of participants
The participant population was men with BC undergoing cystectomy (for MIBC or high-risk non-muscleinvasive BC) with curative intent in the primary setting. Participants with up to clinical stage T4, Nx/N1, and M0 were included. Neo and adjuvant treatment (chemotherapy) was allowed.
Types of intervention and comparator
The following interventions were included:
À Prostate-sparing radical cystectomy: part or the whole prostate is preserved including seminal vesicles, vas deferens, and neurovascular bundles. À Capsule-sparing radical cystectomy: the capsule or peripheral part of the prostate is preserved; however, a transurethral resection of the prostate (TURP) or 
Assessment of risks of bias
The risk of bias (RoB) in the included studies was assessed using the Cochrane RoB assessment tool for RCTs [11] . A modified version of the RoB assessment tool was used in assessing NRCSs with the addition of further domains to assess risk of confounding [12] . A list of the 5 most important potential confounders for harm and benefit outcomes was developed a priori with clinical content experts (EAU muscle-invasive and metastatic BC guideline panel) [9] . The assessment of single-arm case series focussed on reporting biases and external validity [9] . This pragmatic approach is informed by the methodological literature [13, 14] . [24] Capsule sparing ✓ ✓ ✓ ✓ ✓ ✓ ✓ Seminal sparing Nerve sparing Gotsadze et al. [25] Prostate sparing ✓ ✓ ✓ ✓ ✓ Rozet et al. [26] Capsule sparing
Risk of bias and confounding assessments for RCT.
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Data analysis
A narrative synthesis was planned because of the anticipated clinical and methodological heterogeneity in included studies. Descriptive statistics were used to summarize baseline characteristics data. For continuous variables, data were summarized using mean (Ϯstandard deviation) and median (Ϯinterquartile range); for categorical variables, data were summarized using proportions. When time-to-event data were reported by authors using univariate or multivariate models (e.g., Cox regression), data were summarized as hazard ratios and 95% confidence intervals, median survival, and point estimates at specific time points as appropriate. Subgroup and sensitivity analyses were also planned, if data were available, to explore the effect of clinical heterogeneity on the results [9] .
Results
Evidence synthesis
Quantity of evidence identified
In a total of 8,517 abstracts assessed, 26 articles were eligible for full text screening, and 21 articles reporting on 12 studies were included (Fig. 1) .
Characteristics of included studies
Furthermore, 12 studies recruiting a total of 1,098 patients (823 in the intervention group vs. 275 in the control group [ Table 1 ]) were identified, including 9 comparative studies (1 RCT and 2 retrospective NRCSs with matched pair design) [7, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] ] and 3 single-arm case series [25] [26] [27] . The following 3 types of comparisons were found: prostate-sparing vs. radical cystectomy, capsulesparing vs. radical cystectomy, and nerve-sparing vs. radical cystectomy. None of the published studies comparing seminal vesicle-sparing cystectomy vs. radical cystectomy was eligible for inclusion. Further, 2 studies [23, 24] compared different types of sexual-preserving techniques.
In most cases, the open surgical approach was used. Only 3 studies reported that some patients underwent laparoscopic or robotic surgery [17, 23, 24] . The urinary diversion of choice was an orthotopic neobladder in most studies. Only 2 studies reported heterotopic urinary diversions in less than 25% of recruited patients [20, 22] .
Median follow-up ranged from 16.1 to 141 months, and was longer than 3 years in 9 studies [15, 17, 18, 21, [23] [24] [25] [26] [27] , with 3 of them presenting results at a median follow-up longer than 5 years [15, 24, 27] .
Patient selection was different across all the identified studies and is summarized in Table 2 . Median age ranged from 47 to 62 years in the intervention group and from 46 to 61 years in the control group. Prostate cancer was ruled out with digital rectal examination, prostate specific antigen, transrectal biopsy, or biopsy of the prostatic urethra by TURP in all of the sexual function-preserving cystectomy (SPC) techniques, except in those performing nerve-sparing cystectomy where no prostatic tissue was left in place.
RoB and confounding assessment
RoB and confounding assessments for RCT, NRCSs, and case series are presented in Figs. 2-4 . The single RCT [23] had an overall low RoB, whereas for NRCSs, most studies had high RoB across more than 50% of domains. For case series, the overall RoB was moderate. Table 3 . Local recurrence after SPC was commonly defined as any urothelial cancer recurrence below the iliac bifurcation within the pelvic soft tissue and ranged from 7.9 to 61.1% (vs. 15.9%-55.0% in the control group). Metastatic recurrence was reported in only 1 comparative study with rates of 28.6% and 33.3% in both groups [15] . The use of neoadjuvant therapy was scarcely reported and only 2 studies reported some use of adjuvant chemotherapy in this setting [15, 17] . No differences were found in any of the 3 comparative studies reporting oncological outcomes for the prostate-, capsule-, or nerve-sparing techniques (Table 4 and Fig. 5 ).
Furthermore, 2 comparative studies presented results of disease-specific survival (DSS) or OS, showing no statistically significant differences between groups for the prostate-and capsule-sparing techniques at a median follow-up of 3 to 5 years (Table 5) and one of the studies comparing 2 different types of intervention did not show any difference in recurrence-free survival, progression-free survival, DDS, or OS between groups [23] .
For those techniques preserving prostatic tissue (prostate or capsule sparing) rates of incidental prostate cancer in the intervention group ranged from 0% to 15%. Preoperatively, mean PSA ranged from 1.0 to 2.2 ng/ml and postoperatively from 0.1 to 1.53 ng/ml. None of the series reported incidental prostate cancer with Gleason score Z8 (Table 3) .
3.1.4.1.2. Sexual and functional results. Sexual outcomes were evaluated in 832 patients (699 in the intervention group and 133 in the control group) using validatedquestionnaires (international index erectile function; erection hardness score; and BC index) in 8 studies [7, 17, 20, [22] [23] [24] [25] 27] and self-impression reports in 7. Furthermore, 4 studies described some type of ejaculation outcome, such as antegrade or retrograde ejaculation [16, 17, 25, 27] .
Postoperative potency was significantly better than standard cystectomy in the SPC groups in 6 studies comparing SPC vs. RC (P o 0.05), ranging 89.7%, 58.0% to 93.8% and 77.0% to 78.8% for prostate, and capsule or nerve-sparing techniques (Table 6 and Fig. 6 ). Antegrade ejaculation was reported in 7% to 35.5% in 2 studies and 63.2% to 100% reported retrograde ejaculation when addressed.
In the 2 studies comparing different sexual sparing techniques, only Colombo found differences in favor of capsule-sparing cystectomy or seminal-sparing cystectomy over the nerve-sparing cystectomy.
Functional results were evaluated in 917 patients (720 in the intervention group and 197 in the control group). Incontinence was defined as the use of 1 or more pads in most studies. The type of measurement used to evaluate continence varied across all studies. Number of pads was used in 6 studies [16, 17, [19] [20] [21] 24] and self-impression was used in 7 studies, only 1 study [20] used pad test for continence evaluation and 2 studies used voiding diaries [21, 27] .
Daytime continence ranged from 88.9% to 100% and nighttime continence from 55.0% to 88.9% in the SPC with no difference observed in most of the studies. Only 2 comparative studies showed differences in favor of the sexual-preserving techniques [7, 18] (Table 7 and Fig. 7) .
In the 2 studies comparing different SPC techniques, no differences were observed for daytime continence, and only Fig. 4 . Risk of bias and confounding assessments for case series. Colombo found differences in favor of capsule-sparing cystectomy in nighttime continence. Only 1 comparative study [17] presented data of patients dependent on clean intermittent catheterization in both groups. In that study, there were differences in favor of the standard cystectomy (31% in the capsule sparing group vs. 8% in the control group). The rest of the studies, presented rates of clean intermittent catheterization (CIC) for the intervention group that ranged from 2% to 31%. [25] [26] [27] presented Nerve sparing vs. RC
Data from single-arm case series. The 3 singlearm case series included in this review
[23]
Capsule vs. Nv sparing
Colombo et al. [24] Capsule vs. seminal vs. nerve sparing oncological results that were slightly better than in comparative studies of local recurrence (1.2%-4.6%), with similar rates of metastatic recurrence (6.6%-33.3%). DSS and OS at a median time of 5 and 6 years were also better studies for 2 of the studies [26, 27] .
Potency rates ranged from 79.6% to 100% and continence rates were 95.0% to 100% for daytime continence and 31.0% to 96.0% for nighttime continence.
Discussion
Principal findings
The review found that sexual outcomes of postoperative potency were significantly better in the SPC groups compared with standard radical cystectomy in all comparative studies that reported this outcome [7, [17] [18] [19] [20] 22] . In Table 6 Sexual function results addition, large case series of SPC showed potency rates of 79% to 100% [25] [26] [27] . In studies comparing different sparing techniques, conflicting findings were found. Jacobs et al. [23] , the only RCT included in this review, compared capsule-sparing vs. nerve-sparing cystectomy and found potency rates in both groups were not significantly different (50% vs. 40%). Colombo et al. [24] analyzed 3 different techniques, finding capsule-sparing cystectomy and seminal-sparing cystectomy to be superior over nervesparing cystectomy; however, no real conclusions can be drawn due to the limited number of patients included in the study and its retrospective design.
Study
It has been postulated that sparing therapies could have an effect on continence outcome in series with continent urinary diversion. Large cystectomy case series with long follow-up have reported diurnal incontinence rates of 8% to 10% and nocturnal incontinence of 20% to 30% [28, 29] . In this review, continence outcomes were similar in patients submitted to standard cystectomy or to any kind of preserving technique. Only 2 studies showed an improvement in functional outcomes in favor of the sexualpreserving techniques, but considering the low number of patients [18] and the retrospective study design [7] , as well as the wide confidence intervals, these results should be interpreted with caution. When comparing sparing techniques, the RCT of Jacobs et al. [23] , with a primary objective of continence-outcome assessment, showed no differences between capsule-sparing vs. nerve-sparing cystectomy. Finally, there has been a concern that oncological outcomes could be compromised by sparing techniques with an increased risk of widespread unusual metastases [30, 31] . Local recurrence was o20% in all studies except 1 [17] with a median follow-up period of 21 to 102 months, with no significant differences between the prostate-, capsule-, or nerve-sparing techniques. Basiri et al. [17] reported higher rates of local recurrence (61% vs. 55%), with no significant differences between groups. This higher recurrence rate in both groups in the study compared with the other studies may reflect clinical heterogeneity of differences in patient and disease characteristics between the studies. For metastatic disease, only 1 comparative study [15] measured the outcome, with no differences found between groups (29% vs. 33% for prostate-sparing cystectomy vs. radical cystectomy, respectively). The other studies reporting metastatic recurrence were case series showing rates of 0% for nerve-sparing technique [24] and 5% to 33% for prostate or capsule sparing techniques [24] [25] [26] [27] . In 7 studies, the oncological outcomes were presented as recurrence-free survival, progression-free survival, DSS, or OS. No differences were found in the 2 studies comparing prostate-or capsule-sparing cystectomy vs. radical cystectomy [15, 17] , nor in the studies comparing the different SPC techniques [23, 24] . In summary, none of the comparative studies found any differences in oncological outcomes between SPC vs. radical cystectomy, or between the different sparing techniques, regardless of which measure of oncological effectiveness was reported, or the time point of measurement.
Implications for clinical practice and further research
Although sexual-preserving techniques were first described in the 1980s [5] , there are major uncertainties and unanswered questions, including the ideal candidates for these procedures, the most effective technique, the magnitude and nature of functional benefits, and if oncological outcomes are compromised [30, 31] . There is a lack of clear guidelines on the topic. This systematic review was hampered by heterogeneity in the outcomes reported, and lack of standardization in the definitions of outcomes, the tools used to measure the functional outcomes, and the time point at which these outcomes are measured. The field of nerve sparing BC surgery would benefit form a core outcome set [32] and well-designed RCTs [33] . Nonetheless, this study represents the first systematic review addressing the effectiveness of different sexual-preserving cystectomy techniques in men.
Considering all the points previously discussed, the overall oncological results appear to be acceptable, but selection of patients is of paramount importance. Although patient selection was different across all the studies, in the majority, the authors stated some oncological inclusion criteria (i.e., tumor-free in the bladder neck and prostatic urethra, or the presence of organ-confined disease) and some functional criteria as a normal preoperative sexual function, or the age of the patients. A sexual-preserving cystectomy could be offered to motivated men aiming to preserve their sexual function with organ-confined disease and the absence of tumor in the bladder neck, prostate, or prostatic urethra. Magnetic resonance imaging can be considered in the preoperative assessment to improve local staging [1] . Before surgery, and mainly for those techniques where some prostate tissue is left in place, any tumor at the prostate, prostatic urethra, or bladder neck should be ruled out with preoperative PSA, TURP, or transrectal biopsy.
Based on the results of this systematic review, none of the SPC techniques (prostate or capsule or nerve sparing) can be recommended over the others due to the lack of any clear superiority, in the limited number of studies comparing them.
The effect of new techniques and approaches such as robotic surgery on outcomes remains unknown [34] [35] [36] , and only a small number of patients included in this review were operated on with a robot-assisted device. Finally, all of the described preserving techniques have a considerable learning curve, which could hinder the implementation of the procedures even in specialist centers.
Strengths and limitations
The main strength of the review is the robust, reproducible, and transparent methodology based on Cochrane review principles. The review elements, including research questions, participants, interventions, comparison and outcomes, search strategy, and study inclusion and exclusion criteria were developed in conjunction with the EAU MIBC guideline panel, which is a multidisciplinary panel of expert urologists, oncologists, pathologists, radiologists, methodologists, and patient representative. The quality of evidence appraisal was based on meticulous RoB and confounding assessment using standardized tools. The findings of this review were incorporated into the panel's guideline update for 2016. The main limitations include the clinical and methodological heterogeneity present across studies, such that it is difficult to be certain how comparable the results of studies are, and to determine the effect of important confounders on the outcomes. In addition, most studies were small, retrospective nonrandomised studies with moderate to high risks of bias, and confounding, thereby compromising the overall quality of the evidence base. To minimize these limitations, studies with small numbers of participants or short follow-up were excluded.
Conclusion
Prostate-, capsule-, or nerve-sparing cystectomy appear to yield better sexual outcomes compared with standard cystectomy without compromising oncological outcomes. However, the quality of the evidence was low to moderate, and numerous uncertainties remain. As such, until higher quality evidence emerges, it seems prudent to restrict SPC to carefully selected men keen to preserve their sexual function, who have organ-confined disease and absence of tumor in the bladder neck, prostate, or prostatic urethra. Such patients should be carefully counseled regarding the many prevalent uncertainties surrounding the procedure, and closely followed-up and monitored.
